Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution

• Biotage^® PeptiPEC high-throughput kits facilitate fast and low solvent consumption solution for plate-based peptide purification
• Partnership complements Gyros’ PurePep^® EasyClean technology offering with an automated solution for advanced discovery process

Uppsala, Sweden, 07 December 2023: Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, and Biotage, a global life sciences company, providing high-quality purification and sample preparation solutions, today announced a partnership to offer Biotage^® PeptiPEC, based on Gyros’ PurePep^® EasyClean (PEC^TM) catch and release technology, on Biotage^® Extrahera™ automated sample preparation system. The development of an automated plate-based peptide purification workflow provides a fast and environmentally sustainable solution for high-throughput peptide purification.

Biotage PeptiPEC high-throughput kits leverage Gyros Protein Technologies’ proprietary PEC catch and release technology for automation in a plate-based format, enabling scientists to now use the technology to advance drug discovery processes. The PEC technology combined with Biotage Extrahera can purify up to 96 peptides in parallel 75% faster and 98% lower solvent consumption in comparison to sequential HPLC.

Parallel peptide synthesis generates crude peptide samples at a rate that surpasses the capacity of HPLC, the most common method of peptide purification, which is particularly evident when purifying more than 24 peptides simultaneously. The workflow enables scientists to conduct screening and development processes using purified peptides, supporting more robust and accurate processes and results.

Learn more about Biotage® PeptiPEC.

Tomas Blomquist, CEO, Biotage, said: “We’re excited to be partnering with Gyros Protein Technologies to bring a plate-based automated solution for parallel high-throughput peptide purification to market, removing bottlenecks for peptide scientists, and providing a complete workflow solution from synthesis to evaporation. This partnership strengthens our position in the rapidly growing peptide market and supports our mission to provide high-quality, end-to-end separation and sample preparation solutions to scientists all over the world.”

Mark Vossenaar, Vice President, General Manager, Biopharmaceutical Development Division at Mesa Labs, commented: “By partnering with Biotage, we are taking a step further in our commitment to provide scientists with state-of-the-art peptide solutions across the entire value chain, from early research and screening to large-scale peptide production. The availability of our proprietary PEC purification for automation in a plate-based format is equipping researchers with faster and more sustainable processes to advance their drug discovery."

Media Contact:

Saara Nordenström
Biotage
Tel: +46 76 142 2612
Email: saara.nordenstrom@biotage.com 

About Gyros Protein Technologies https://www.gyrosproteintechnologies.com/

Gyros Protein Technologies enables bioanalytical solutions and peptide synthesis, helping scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab^® xPand, and Gyrolab xPlore™, and Gyrolab immunoassay kits are used by scientists at leading pharmaceutical, biotech, CRO, and CMO companies in the development and manufacturing of various biotherapies including those based on peptides, antibodies, cell and gene therapies and vaccines. Gyrolab immunoassays provide key workflow advantages of speed, automation, and low reagent usage, and assay quality advantages of wide dynamic range with robust precision and reproducibility in applications including pharmacokinetics/pharmacodynamics, immunogenicity, and analysis of bioprocess-related impurities. Our low to mid-scale peptide synthesizer platforms, PurePep^® Chorus, Symphony^® X, and PurePep^® Sonata+, and chemistries deliver uncompromising purity, flexibility, and quality synthesis for discovery and pre-clinical studies of simple to complex multifunctional peptides. The PurePep^® EasyClean (PEC^TM) technology complements the PurePep^® portfolio with Kits and Services for orthogonal peptide purification and modification from research to commercial scale. Our peptide synthesis and bioanalytical solutions accelerate the discovery, development, and manufacturing of safer biotherapeutics. Gyros Protein Technologies is part of the Biopharmaceutical Development Division of Mesa Laboratories, Inc. (Nasdaq: MLAB).

About Biotage www.biotage.com

Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.

Biotage is contributing to sustainable science with the goal to make the world a healthier, greener, and cleaner place – HumanKind Unlimited.

Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.

Biotage is headquartered in Uppsala in Sweden and employs appr. 700 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.

Forward Looking Statements

This release contains “forward-looking statements” – that is, statements that relate to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, expectations regarding our products, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operation” in Mesa Laboratories, Inc.’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.